Q-omics provides the consensus-scored SNORD11B profile across patient tissues and cancer cell-line models. SNORD11B expression is associated with patient survival in 13 of 34 cancer types, with the highest sampling consensus in DLBC. Among the 18 cancer types available for tumor–normal comparison, SNORD11B is differentially expressed in 6, with the highest sampling consensus in STAD. Additionally, SNORD11B RNA expression shows 9,397 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight DLBC, STAD, and LSCC as cancer lineages where SNORD11B shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SNORD11B — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SNORD11B survival associations across molecular data types. SNORD11B RNA expression shows survival associations in the most cancer types (13). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SNORD11B RNA expression–survival associations across cancer types. High SNORD11B expression shows unfavorable associations in DLBC, MESO, LIHC, UCEC, PRAD and THCA. The DLBC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .002). Together, the overview and detailed table identify DLBC as the clearest survival context for SNORD11B RNA expression.
This table summarizes SNORD11B tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 6. The strongest signals are observed in LUSC for RNA.
This table ranks reproducible tumor–normal expression differences for SNORD11B. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SNORD11B shows higher tumor expression in STAD, LUSC, LIHC, KIRC, BLCA and LUAD. The STAD box plot shows higher SNORD11B RNA expression in tumor versus normal tissue (log2 FC = +0.510, t-test p = .005).
This table shows molecular features associated with SNORD11B in patient tissues and cancer cell lines. In patient samples, SNORD11B shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set.
